Skip to main content
SpringerLink
Log in

Nierenzellkarzinom

Multimodale Therapie im 21. Jahrhundert

  • TOPIC 1 · nierenzellkarzinom
  • Published:
best practice onkologie Aims and scope

Die Behandlung des Nierenzellkarzinoms ist in den letzten Jahren deutlich facettenreicher geworden. Neben der radikalen Nephrektomie stellen organerhaltende und laparoskopische Operationen Standardverfahren dar. In der Systemtherapie stehen seit 2006 neben der Immuntherapie zwei potente Breitspektrum-Kinase-Inhibitoren („multi-target tyrosine kinase inhibitors“, MTKI) zur Verfügung. Weitere molekulare Substanzen drängen in die Klinik. In fortgeschrittenen Stadien profitieren Patienten darüber hinaus von lokaltherapeutischen und palliativ-chirurgischen Maßnahmen. Der Stellenwert einzelner Modalitäten untereinander als auch deren Kombination in multimodalen Therapieansätzen bleibt noch zu klären. Unter Beachtung der gegenwärtigen Datenlage geben wir im Folgenden einen Überblick über die therapeutischen Möglichkeiten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. National Comprehensive Cancer Network Clinical Pracitce Guideliness in Oncology. Kindey Cancer. V.I.2008. www.nccn. org

  2. Motzer RJ, Bacik J, Murphy BA et al. (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 20: 289–296

    Article  PubMed  CAS  Google Scholar 

  3. Lee CT, Katz J, Shi W et al. (2000) Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol. 163: 730–736

    Article  PubMed  CAS  Google Scholar 

  4. Delakas D, Karyotis L, Daskalopoulos G et al. (2002) Nephron-sparing surgery for localized renal cell carcinoma with a normal conralateral kidney: a European three-center experience. Urology. 60: 998–1002

    Article  PubMed  Google Scholar 

  5. Fergany AF, Hafez KS, Novick AC (2000). Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol. 163: 442–445

    Article  PubMed  CAS  Google Scholar 

  6. Kavolius JP, Mastorakos DP, Pavlovich C et al. (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261–2266

    PubMed  CAS  Google Scholar 

  7. Eggener SE, Yossepowitch O, Pettus JA et al. (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24: 3101–3106

    Article  PubMed  Google Scholar 

  8. Coppin C, Porzsolt F, Awa A et al. (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev: CD001425

  9. Négrier S, Gomez F, Douillard JY et al. (2005) Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol. 23: 161–165

    Article  PubMed  Google Scholar 

  10. Ulutin HC, Aksu G, Fayda M et al. (2006) The value ofpostoperative radiotherapy in renal cell carcinoma: a single-institution experience. Tumori 92: 202–206

    PubMed  Google Scholar 

  11. Svedman C, Sandström P, Pisa P et al. (2006) A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006; 45: 870–875

    Article  PubMed  Google Scholar 

  12. Lee J, Hodgson D, Chow E et al. (2005) A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer; 104: 1894–1900

    Article  PubMed  Google Scholar 

  13. Chang EL, Selek U, Hassenbusch SJ 3rd et al. (2005) Outcome variation among “radioresistant“” brain metastases treated with stereotactic radiosurgery. Neurosurgery 56: 936–945

    PubMed  Google Scholar 

  14. Ernst-Stecken A, Ganslandt O, Lambrecht U et al. (2006) Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. Radiother Oncol; 81: 18--24

    Article  PubMed  Google Scholar 

  15. Senan S, Smit EF (2007) Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist;12: 465--477

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover

    P. Ivanyi, A. Ganser &  V. Grünwald

  2. Klinik und Poliklinik für Urologie und Kinderurologie, Medizinische Hochschule Hannover, Hannover

    M. Al-Jundi

  3. Klinik für Strahlentherapie und Spezielle Onkologie, Medizinische Hochschule Hannover, Hannover

    M. Bremer

  4. Medizinische Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Carl-Neuberg-Str.1, 30625, Hannover

    V. Grünwald

Authors
  1. P. Ivanyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Al-Jundi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Ganser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Grünwald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Grünwald.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ivanyi, P., Al-Jundi, M., Bremer, M. et al. Nierenzellkarzinom. best practice onkologie 2, 4–13 (2007). https://doi.org/10.1007/s11654-007-0029-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-007-0029-0

Search

Navigation